Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported R&D Expense of $121.20 million for fiscal year 2025.
BridgeBio Oncology Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $121.20M | +65.8% |
| 2024 | $73.11M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $35.05M | +95.9% | +95.9% |
| September 30, 2024 | $17.89M | — | — |
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +65.8% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, BridgeBio Oncology Therapeutics, Inc.’s r&d expense has grown by 65.8% (from $73.11 million to $121.20 million).
- The most recent figure is from BridgeBio Oncology Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: